Fundamental Analysis of Eli Lilly and Company - Growth / Value Index
LLY - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.636
Book Value in last 3 years is trending up
Tsr Value Index - Very Poor Score of 7.81
Price to Earning Ratio is 110.25 and EV to EBITDA is 264.46 suggesting that it is very expensive
Price to Book Ratio of 58.83 suggesting that it is very expensive
Valuation Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Price to Earning | 111.12 | 139.43 | 25.00 % | |
Price to Book | 59.30 | 64.02 | -0.959 % | 53.96 |
Price to Sales | 18.98 | 21.69 | -11.14 % | |
Enterprise Value to EBITDA Multiple | 266.48 | 62.82 | -28.76 % |
LLY - Profitability Highlights
Profitability Analysis
Over the last 3 years, the company has achieved Incredible Return on Equity
Company Earning excess return
During the past twelve months, the company has given a strong Return On Equity of 53.79%
Company's Net Profit is increasing for last 5 Quarters
Company's Profit Before Tax is increasing for last 5 Quarters
EBITDA is continuously increasing for last 3 Years
Steady Growth in EPS for last four quarters
Good Return On Capital Employed of 14.56
Good Net Margin of 17.08% is achieved by the company
Very Low Dividend Yield of 0.680 %
Profitability Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Return On Equity | 53.79 | 46.31 | -21.02 % | 17.51 |
Return On Asset | 10.45 | 7.79 | -38.24 % | 3.51 |
Net Profit Margin | 17.08 | 15.55 | -28.91 % | 25.58 |
Operating Profit Margin | 4.87 | 30.91 | 6.55 % | 29.88 |
EBITDA Margin | 7.88 | 35.63 | 26.18 % | 36.62 |
Highlights
Market Cap | 731811 M |
Enterprise Value | 754218 M |
Price/Book TTM | 59.30 |
Outstanding Share | 950404 K |
Float/ Outstanding Share | 94.50% |
Dividend Yield | 0.670 % |
Share Holding
Guru Numbers
Price/Graham No | 17.78 |
Peter Lynch Ratio | -0.180 |
Piotroski F Score | 6.00 |
Altman Z Score | 9.47 |
Sloan Ratio | 0.100 |
Peter Lynch Fair Value | 104.09 |
LLY - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Steady increase in Total Assets for last 3 Years
Tsr Growth Index - Very Poor Score of 17.66
Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field | TTM | YoY Growth | QoQ Growth |
---|---|---|---|
Revenue | 35932.10 M | 12.37 % | 6.26 % |
Gross Profit | 19572.60 M | 15.15 % | 5.99 % |
EBITDA | 2830.30 M | 41.79 % | 10.90 % |
Net Profit | 6138.40 M | 20.12 % | 2.43 % |
EPS | 6.93 | 20.00 % | NA |
LLY - Stability Highlights
Stability Analysis
Altman Z Score of 9.41 suggests good Stability
Company has high debt burden
Company is unable to generate enough free cash to support the business.
Stability Key Ratios
Ratio | Latest FY | Yoy Change | MRQ |
---|---|---|---|
Debt to Equity Ratio | 2.34 | 53.58 % | 2.05 |
Cash Ratio | 0.107 | -16.88 % | |
Quick Ratio | 0.731 | -8.71 % | 1.03 |
Shareholders Equity | 16.83 | -21.79 % | |
Debt to EBITDA | 2.21 | 9.56 % |
Historical Valuation Ratios of Eli Lilly and Company
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Eli Lilly and Company
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Eli Lilly and Company
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Eli Lilly and Company
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)